Lessons for COVID-19 Immunity from Other Coronavirus Infections - PubMed (original) (raw)

Review

Lessons for COVID-19 Immunity from Other Coronavirus Infections

Alan Sariol et al. Immunity. 2020.

Abstract

A key goal to controlling coronavirus disease 2019 (COVID-19) is developing an effective vaccine. Development of a vaccine requires knowledge of what constitutes a protective immune response and also features that might be pathogenic. Protective and pathogenic aspects of the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not well understood, partly because the virus has infected humans for only 6 months. However, insight into coronavirus immunity can be informed by previous studies of immune responses to non-human coronaviruses, common cold coronaviruses, and SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Here, we review the literature describing these responses and discuss their relevance to the SARS-CoV-2 immune response.

Copyright © 2020 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests The authors declare no competing interests.

Figures

Figure 1

Figure 1

Genomic Organization and Virion Structure (A) Schematic of the 30-kb SARS-CoV-2 genome. The first two-thirds of CoV genomes encode a polyprotein that is cleaved into constituent nonstructural proteins involved in replication and immune evasion, while the remaining one-third encodes the four main structural proteins (S, E, M, and N), along with accessory proteins. (B) Schematic representation of a CoV virion. gRNA, genomic RNA.

Figure 2

Figure 2

Human Coronavirus Tropism and Longevity of Immune Responses Schematic depicting sites of replication of human coronaviruses (A) and schematic of longevity of immune responses to common cold coronaviruses, SARS-CoV, and MERS-CoV (B) (not drawn to scale). Data not available for antibody longevity in patients following mild disease caused by SARS-CoV.

Similar articles

Cited by

References

    1. Adams E.R., Ainsworth M., Anand R., Andersson M.I., Auckland K., Baillie J.K., Barnes E., Beer S., Bell J., Berry T., et al. Antibody testing for COVID-19: a report from the National COVID Scientific Advisory Panel. medRxiv. 2020 doi: 10.1101/2020.04.15.20066407. - DOI - PMC - PubMed
    1. Akerström S., Tan Y.-J., Mirazimi A. Amino acids 15-28 in the ectodomain of SARS coronavirus 3a protein induces neutralizing antibodies. FEBS Lett. 2006;580:3799–3803. - PMC - PubMed
    1. Alsaad K.O., Hajeer A.H., Al Balwi M., Al Moaiqel M., Al Oudah N., Al Ajlan A., AlJohani S., Alsolamy S., Gmati G.E., Balkhy H., et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection - clinicopathological and ultrastructural study. Histopathology. 2018;72:516–524. - PMC - PubMed
    1. Anghelina D., Pewe L., Perlman S. Pathogenic role for virus-specific CD4 T cells in mice with coronavirus-induced acute encephalitis. Am. J. Pathol. 2006;169:209–222. - PMC - PubMed
    1. Anghelina D., Zhao J., Trandem K., Perlman S. Role of regulatory T cells in coronavirus-induced acute encephalitis. Virology. 2009;385:358–367. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources